Please assess the completion status of the following clinical trial:

Trial Title: Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Patients who are recipients of a renal transplant.~2. Patients treated with an immunosuppressive regiment including MMF before recruitment.~3. Patients suffering from GI side effects related to MMF standard doses or patients treated with a reduced MMF dose to control the aforementioned GI side effects.~4. Patients 18 years or older.~5. Patients who have given written informed consent to participate in the study~6. Patients complying with all study requirements including completing questionnaires and attending to the three study visits.~Exclusion criteria~1. Patients with GI symptoms assumed or known not to be caused by MPA therapy (eg. oral bisphosphonate induced, infectious diarrhea)~2. Acute rejection less than 1 week before recruitment.~3. Females of childbearing potential who are pregnant, planning to get pregnant and/or breast feeding or not willing to practice an approved method of birth control.~4. Presence of psychiatric disorder, such as schizophrenia or major depression, in the investigator's opinion, could interfere with study requirements.~5. Patients undergoing surgery due to acute illness or hospitalized.~6. Existence of any medical condition which, in the investigator's opinion based on anamnesis or medical records, could affect study completion, including but not limiting visual problems or cognitive deterioration.~7. Patients currently treated or who have been treated with any other study drug or treatment within 30 days prior to baseline visit.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- EC MPS (Type: EXPERIMENTAL): Up to 1440mg taken in two doses
- Mycophenolate mofetil (Type: ACTIVE_COMPARATOR): 250 mg or 500 mg in two equal doses

Based on this trial design, predict the completion outcome and termination type (if applicable).